A few series of indole derivatives were screened for antimicrobial, antifungal and anti-HBV activities. The compounds were tested for their in vitro antibacterial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli and for their antifungal activity against Candida albicans using a disc diffusion method, which measures the diameter of the inhibition zone around a paper disc soaked in a solution of the test compounds. The antimicrobial activity results showed that all compounds are as a active as the standard compound ampicillin against Staphylococcus aureus. It was also found that indole carboxamide derivatives, substituted at 3-position with several benzyl groups, showed better inhibition of Bacillus subtilis than their congeners substituted at 2-position. Activity patterns of the compounds against Escherichia coli and Staphylococcus aureus were found slightly different by the same method. In this case, there was no correlation between structure and activity of the compounds. The antifungal activity of carboxamide derivatives was found higher compared to that of the propanamide derivatives. The minimum inhibitory concentration (MIC) values of some indole derivatives were also determined by the tube dilution technique. The MIC values of the compounds were found nearly 20-to 100-fold smaller compared to the standard compounds ciprofloxacin and ampicillin (1.56Ð3.13 μg/ml and 1.56Ð12.5 μg/ml, respectively) against Staphylococcus aureus, Bacillus subtilis and Escherichia coli. The MIC values of the tested compounds showed that these are better inhibitors for Candida albicans. Indole derivatives were screened by the anti-HBV susceptibility test. No compound showed good inhibition against the HBV virus.
Introduction
Indole derivatives have been found to possess a wide range of biological activities such as anticonvulsant, antidepressant, antihistamine, antitubercular, cardiovascular, antidiabetic, anti-inflammatory, anthelmintic, antiallergic, antiviral, antifungal and antimicrobial activities (Mehta et al., 2005) .
A lot of simple indole derivatives was reported as antimicrobial and antifungal agents in several studies. Among them ethyl-3-indolylacrylate, 5-bromo-3-(2-cyanovinyl)indole and 3-(2-nitrovinyl)-indole were found active against a wide variety of microorganisms. Haloindoles were also found highly active at concentrations of 10Ð100 μg/ml (Whitehead and Whitesitt, 1974) . Another study demonstrated that some 3-acyl-4,7-dihydroxy indoles have antibacterial properties against Escheri-0939Ð5075/2008/0300Ð0189 $ 06.00 " 2008 Verlag der Zeitschrift für Naturforschung, Tübingen · http://www.znaturforsch.com · D chia coli and Streptococcus pyogenes (Malesani et al., 1975) . 1-Morpholino-3-carbethoxy-5-hydroxy-2-methylindole was reported to be highly active against Escherichia coli and Bacillus cirroflagellosus (Donawade and Gadaginamath, 2005) . 1-(4-Phenyl) and (1-naphthyl-4H-1,2,4-triazole-5-thion-3-yl)indoles exhibited strong antibacterial and antifungal activities (Tsotinis et al., 1997) . Some indole-containing derivatives of thiosemicarbazide and their cyclic 1,2,4-triazole and 1,3,4-thiadiazole analogues were found to be selective antimicrobial and antifungal agents (Varvaresou et al., 2000) . Antimicrobial activities of several indole derivatives fused with heterocyclic compounds were also investigated. Among them, 4H-pyrano[2,3-f]indole, benzotetrahydrocyclohept [1,2-b] indole, and 1-triazolylethylbenz[g]indole derivatives showed considerable antimicrobial activities (Macchia et al., 1996; Gadaginamath and Kavali, 1999; Bhovi and Gadaginamath, 2005) .
Some indole compounds also exhibited a remarkable potential of antiviral activity. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide derivatives were reported as HIV-1 reverse transcriptase inhibitors with nanomolar IC 50 values (Williams et al., 1993 ). An indole-containing non-nucleoside reverse transcriptase inhibitor, delavirdine (Rescriptor " ), was approved as a commercial anti-HIV drug (Romero et al., 1996) . N-Alkyl-substituted indolocarbazoles were found to be potent inhibitors of human cytomegalovirus in nanomolar ranges (Slater et al., 2001) . 6-Bromo-6-hydroxy-1H-indole-3-carboxylate derivatives were reported as anti-influenza virus inhibitors (Zhao et al., 2004) . Some tetracyclic indole derivatives showed anti-HCV activity with IC 50 values below 5 μm (Conte et al., 2006) . Some oxoindole derivatives were found to be potent HIV-1 non-nucleoside reverse transcriptase inhibitors (Jiang et al., 2006) . Recently, N-morpholinoacetyl-2-phenyl-indole-6-carboxylic acid was determined as potent inhibitor of subgenomic hepatitis C virus replication with an IC 50 value of 0.127 μm (Harper et al., 2005 ). Another research group also reported the compound N-methyl-2-phenyl-3-cyclohexyl-indole-6-carboxylic acid as allosteric inhibitor of the HCV virus (IC 50 0.009 μm) (Beaulieu et al., 2006) . Hepatitis B virus (HBV) is the major cause of acute and chronic hepatitis which could lead to hepatocellular carcinoma. The wide prevalence of chronic HBV infection together with the lack of an effective drug available for the treatment warrants the search for novel therapeutic agents against the virus (Tan et al., 2006) . Current approaches to the development of a therapy for HBV infection are centered mainly on nucleoside analogues targeting HBV reverse transcriptase/ polymerase (Ying et al., 2003) . The major problem using nucleoside analogues as therapeutic agents is the emergence of resistant viruses. Various nonnucleoside analogues such as phenylpropenamide derivatives (Delaney et al., 2002) , iminosugars (Mehta et al., 2001) , heteroarylpyrimidines (Weber et al., 2002) have all been shown to be selective inhibitors of hepatitis B virus replication. These inhibitors do not target HBV reverse transcriptase but they prevent the encapsidation of viral pregenomic RNA. None of the non-nucleoside indole derivatives are reported as anti-HBV agent so far, although some indole derivatives have been found to be strong inhibitors of HCV and HIV.
In the framework of the above studies, we aimed to test some novel NÐH, N-substituted indole-2-and -3-carboxamides ( Fig. 1) and NÐH, N-substituted indole-3-propanamide derivatives (Fig. 2) , which were previously synthesized and reported as antioxidant agents (Bozkaya et al., 2007; Ölgen et al., 2007a, b) , in order to identify their possible antimicrobial, antifungal and anti-HBV activities. In the present investigation, the in vitro activity of the compounds was determined by a disc diffusion method and the MIC values of the compounds were calculated by the tube dilution technique. Indole derivatives were also tested for their anti-HBV activity by in vitro replication of the HepAD38 cell line and the anti-HBV susceptibility test.
Experimental

Disc diffusion method
Antibacterial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and antifungal activity against Candida albicans were investigated by the disc diffusion method (Tunçbilek et al., 1999) . Mueller-Hinton agar (MHA, DIFCO, Detroit, MI, USA) was melted at 100 ∞C, and after cooling to 56 ∞C, it was poured into Petri plates of 9 cm diameter in quantities of 20 ml, and left on a flat surface to solidify. The surface of the medium was dried at 37 ∞C. After the culture of each bacterium and yeast strain was kept in Mueller-Hinton broth at 37 ∞C for 18Ð24 h and diluted with Mueller-Hinton broth to 10 5 cfu/ml, they were pipetted into Mueller-Hinton agar plates prepared as described above. The surface of the medium was allowed to dry. The paper disc (8 mm in diameter) was soaked in 3000 μm (in propylene glycol as a blank; it has no inhibition zone) compound and was applied to the surface of inoculated plates. After 18Ð24 h of incubation at 37 ∞C, the Petri plates were examined and the diameter of the growth inhibition zone around the paper disc was measured. The activity results of tested compounds and references are shown in Table I .
Tube dilution technique
The in vitro antimicrobial and antifungal activities of compounds were also tested by the tube dilution technique (Tunçbilek and Altanlar, 2006 (ATCC 10145) . The bacterial strains were maintained on MHA a medium for 24 h at 37 ∞C and fungi were maintained on SDA (Sabouraud dextrose agar) for 2Ð5 d at (25 ð 1) ∞C. The bacteria and fungi inocula were prepared by suspension in 9 ml of sterile water for colonies from a culture on MHA and SDA medium. The cell density of each inoculum was adjusted in sterile water of a 0.5 Mc Farland standard. The final inoculum size was 10 5 cfu/ml and 10 4 cfu/ml for the bacteria and fungi, respectively. Microbial inocula were added to the two-fold diluted samples, and each experiment in the antibacterial and antifungal assays was replicated twice. A set of tubes containing only inoculated broth was used as control. After incubation of the bacteria for 18Ð24 h at (37 ð 1) ∞C and of the fungi for 2Ð5 d at (25 ð 1) ∞C, the last tube with no growth of microorganisms was recorded to represent the MIC value expressed in μg/ml.
In vitro replication of HepAD38 cell line and anti-HBV susceptibility testing of novel molecules
The in vitro replication ability of the HepAD38 cell line (was kindly gifted by Raymond F. Schinazi, Emory University, Atlanta, USA) was tested in the presence of the novel molecules synthesized. 24-Well plates were seeded with 5 · 10 4 HepAD38 cells in growth medium contaning DMEM/Ham's F12 supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 IU/ml penicillin/50 μg/ml streptomycin mix, 400 μg/ml G418, and 0.3 μg/ml tetracycline. In order to initiate viral replication, growth medium was changed with assay medium by the withdrawal of tetracycline. Two days post seeding, cells were fed with fresh assay medium alone to test the replication efficiency or with assay medium containing increasing concentrations (0.1, 1, 10 and 100 μm) of the compounds. The supernatant of the cells fed with only fresh assay medium was collected every day during 5 d, and the supernatant of the cells fed with the drugcontaining assay medium was collected at the end of the fifth day. Viral DNA extraction was performed using "QIAamp DNA Mini Kit" (Qiagen, Basel, Switzerland) according to the manufacturer's instructions. The HBV DNA was measured with a real-time PCR method using hybridization probes and "Fast Start DNA Hybridization Kit" (Roche Diagnostics, GmbH, Indianapolis, IN, USA) according to a previously published protocol (Bozkaya et al., 2005) . Two independent experiments were performed for each drug. Lamivudine (3TC, 2Ј,3Ј-dideoxy-3Ј-thiacytidine), whose anti-HBV activity is well documented (Borgia and Gentile, 2006), was used as positive control.
Results and Discussion
All compounds (Figs. 1 and 2) were tested in vitro for their antimicrobial activity against Bacillus subtilis, Escherichia coli, Staphylococcus aureus using ampicillin and ciprofloxacin as a standard and for their antifungal activity against Candida albicans using miconazole as a standard. The compounds were dissolved in propylene glycol (PGG) at concentrations of 0.2Ð0.22 mg/ml. PGG did not show any inhibitory effect on the growth of the test organisms. Table I shows the results of the in vitro activity determination by the disc diffissuion method (Tunçbilek et al., 1999) . More propanamide derivatives have bigger inhibition zones than carboxamide derivatives, which represent their better activity. Moreover, the antimicrobial activity results obtained from this assay showed that all compounds and ampicillin are almost equally active against Staphylococcus aureus. Indoles substituted at position 3 with several benzyl groups were found more active against Bacillus subtilis than their congeners substituted at position 2. Comparison of the activity results between substituted phenyl-or substituted benzyl-containing indole carboxamides at either the 2-or 3-position showed that most of the substituted phenyl derivatives have higer activity. The N-unsubstituted indole propanamide compounds 27 and 28 are better inhibitors of Bacillus subtilis than the other nonsubstituted compounds at the 1-position. Activity patterns of the compounds against Escherichia coli and Staphylococcus aureus were found slightly different. In this case, there was no correlation between the structure and activity of the compounds. N-Substituted indole with halogen substituents of the benzamide ring at 3-position enhanced the antimicrobial activity more than their congeners substituted at 2-position. In addition, the N-unsubstituted compounds 1 and 2 with a halogensubstituted aniline side chain at 2-position showed higher activity against Candida albicans than the other N-unsubstituted congeners. In general, almost all NÐH and N-substituted indole-2-and -3-carboxamide derivatives showed a larger inhibition zone against Candida albicans than NÐH and N-p-fluorobenzyl-substituted propanamide derivatives. We can assume that the carboxamide derivatives are better antifungal compounds than the propanamide derivatives.
The MIC values of the compounds were determined by the two-fold serial dilution technique for the antibacterial and antifungal assay in MuellerHinton broth and Sabouraud dextrose agar, respectively (Tunçbilek and Altanlar, 2006) . The activity results are shown in Table II . Some indole derivatives, which showed a bigger inhibition zone by the disc diffusion method, were picked to determine their MIC values. No compound was found active against Staphylococcus aureus, Bacillus subtilis and Escherichia coli compared with ciprofloxacin. The tested compounds showed slight inhibition in the range 6.56Ð13.12 μg/ml against Candida albicans. In general, the activity results reveal that the small structural differences can have a great influences on the antimicrobial activity. The same substitution pattern on different positions of indole-2-and -3-carboxamide may lead to a different role in the inhibition of microorganisms. Consequently, the antimicrobial and antifungal screening of indole carboxamide and propanamide derivatives, and moreover information obtained from literature give us a new direction to design a concept of new indole derivatives. Especially, it was found that most of our compounds are more active as antifungals than as antibacterials, which could guide us to design new lead antifungal indole derivatives.
Some simple indole derivatives with mixed antifungal and antibacterial activities were converted by Whitehead and Whitesitt (1974) to antibacterial compounds by introducing an appropriate diarylmethyl substituent. These investigators also increased the antifungal activity of 5-bromoindole 2Ð25 times by adding the diphenylmethyl group to the 3-position. The compound 5-bromoindole inhibited six of the fungal species and was considered as an effective antifungal agent of the simple indoles. Inspired by these studies, instead of an amide group, insertion of a halogen-substituted aromatic ring at 2-and 3-position of indole and concurrent substitutions at position 5 of the indole with halogens especially with bromine are underway to test these modifications for biological activity. Indole derivatives were also tested for the in vitro replication of the HepAD38 cell line, and the anti-HBV susceptibility was compared with that of lamivudine. The IC 50 values of all compounds were found Ͼ1000 μm against HBV and the one for lamivudine was detected as 0.29 μm at the same reaction conditions. It is known that the treatment of chronic hepatitis B infection is based on the suppression of viral replication. To date, this is achieved by either interferon-α or nucleo-side analogues. There is no certain structure for non-nucleoside analogues useful as inhibitors of HBV. Most of them were developed to block the proper formation of nucleocapsid of HBV (Wen et al., 2003) , and they showed potent inhibition of HBV replication in vitro and in vivo. Conclusion from findings in literature suggests that to identify a new lead by randomly compounds or from preselected chemical libraries, determination of antiviral selectivity and specificity of newly discovered active compounds are still practical tools to discover new anti-HBV drugs. Although several therapeutic options now exist to cure HBV infection, Beaulieu P. L., Gillard J., Bykowski D., Brochu C., Dansereau N., Duceppe J.-S., Hache B., Jakalian A., Lagace L., La Plante S., Mcercher G., Moreau E., Perreault S., Stammers T., Thauvette L., Warrington J., and Kukolj G. the poor response rate and the development of resistant mutants highlight the need for alternative drugs. Since some indole derivatives exhibited some antiviral activity and organized serendipity can still play an important role to discover new drug candidates, there is a chance to have active indole derivatives against HBV infections in future.
